Roche and Bayer are expanding their companion Dx collaboration; Quest Diagnostics snatched up Summit Health;

> Roche ($RHHBY) and Bayer have expanded their companion diagnostics collaboration into multiple projects. Story

> Harvard Medical School and Columbia University won grants of about $12.3 million this year from the National Institute of Allergy and Infectious Diseases to develop translational research centers focused on molecular diagnostics technologies. Story (reg. req)

> Exosome Diagnostics raised a $27 million Series B round, led by Qiagen ($QGEN) and Arcus Ventures, to help propel its prostate cancer urine test to market. Story

> Seattle's Pacific Biomarkers will use its biomarker assays in a collaboration deal with Shanghai's WuXi PharmaTech ($WX) focused on the development of new treatments. Release

> Quest Diagnostics ($DGX) said it will buy Summit Health, an Arizona company that provides finger-stick diagnostics and other biometric screenings. Financial terms were not disclosed. Release

> NeuroMetrix ($NURO) plans to seek regulatory approval in Japan for its point-of-care test to detect diabetic peripheral neuropathy. Release

Sponsored By Paraza Pharma

Choosing the Right Pre-Clinical Collaborative Research Organization (CRO)

Learn about the key factors that are essential to creating a collaborative and productive working relationship to advance pre-clinical drug discovery programs.